evaluating the therapeutic potential of pik3ca-derived public neoantigens
Published 2 years ago • 255 plays • Length 3:25Download video MP4
Download video MP3
Similar videos
-
0:57
the potential of the tsafinder tool in hematological oncology
-
1:59
the optec study: evaluating outpatient step-up administration of teclistamab in pts with r/r myeloma
-
1:40
new therapeutic approaches targeting xpo1-overexpression in tp53-mutated myeloid malignancies
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
2:41
cell avidity as a predictor of t-cell efficacy
-
3:13
how to optimally sequence agents in the expanding treatment armamentarium of multiple myeloma
-
2:12
the optimal sequencing of therapies in waldenström’s macroglobulinemia
-
14:52
adverum biotechnologies
-
1:02:27
john chaput | a nucleic acid approach to antibody therapeutics
-
1:06:04
itp: novel treatments
-
2:00
comprehensive assessment of myeloid malignancies with oncomine myeloid research assay
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
4:53
bio-plex® multiplex system is key in novel melanoma therapeutics study
-
59:47
clinical proteogenomic tumor analysis consortium
-
2:26
trk inhibition’s future role in precision medicine
-
1:32
shifting the treatment landscape of itp: novel agents and future outlooks
-
1:00
proof of principle to progress treatments
-
4:20
therapy-related all: etiology, prognosis, and treatment
-
7:09
how to run the invitrogen proquantum high sensitivity immunoassay kit
-
1:52
molecular testing in the uk
-
3:05
about precision medicine
-
1:08
novel strategies to target p53-mutant hematological malignancies